A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT03831191 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

136

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated for lack of efficacy after an interim analysis was performed

Conditions

Atopic Dermatitis

Interventions

DRUG: LY3375880
DRUG: Placebo

Sponsor

Eli Lilly and Company